loading...| Preferred Name |
Clarithromycin |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1054 |
| Accepted_Therapeutic_Use_For |
H. pylori infection; Various bacterial infections |
| ALT_DEFINITION |
An antibiotic drug used to treat infection. It belongs to the family of drugs called macrolides. |
| CAS_Registry |
81103-11-9 |
| CHEBI_ID |
CHEBI:3732 |
| Chemical_Formula |
C38H69NO13 |
| code |
C1054 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A semisynthetic 14-membered ring macrolide antibiotic. Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms. Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04) |
| Display_Name |
Clarithromycin |
| FDA_UNII_Code |
H1250JIK0A |
| FULL_SYN |
6-O-Methylerythromycin Biaxin Abbott-56268 |
| label |
Clarithromycin |
| Legacy_Concept_Name |
Clarithromycin |
| NSC_Code |
643733 |
| PDQ_Closed_Trial_Search_ID |
42308 |
| PDQ_Open_Trial_Search_ID |
42308 |
| Preferred_Name |
Clarithromycin |
| prefixIRI |
C1054 |
| prefLabel |
Clarithromycin |
| Semantic_Type |
Organic Chemical Antibiotic |
| UMLS_CUI |
C0055856 |
| subClassOf |